×
About 7,973 results

ALLMedicine™ Angioedema Center

Research & Reviews  1,793 results

Atopic Keratoconjunctivitis (AKC)
https://emedicine.medscape.com/article/1194480-print

Feb 3rd, 2023 - Background Atopic keratoconjunctivitis (AKC) is a relatively uncommon but potentially blinding ocular condition. In 1952, Hogan described this disease as a bilateral conjunctivitis occurring in 5 male patients with atopic dermatitis. Originally re...

C1-inhibitor/C1-inhibitor antibody complexes in acquired angioedema due to C1-inhibitor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890765
Orphanet Journal of Rare Diseases; Polai Z, Kajdacsi E et. al.

Feb 3rd, 2023 - Autoantibodies against C1-inhibitor (C1-INH-Ab) have a diagnostic value in acquired angioedema due to C1-inhibitor deficiency (C1-INH-AAE), even though antibodies can circulate in complexes, which can be undetectable by proven methods. Our aim was...

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)
https://clinicaltrials.gov/ct2/show/NCT04278885

Feb 2nd, 2023 - Factor XII is a serine protease with diverse functions that participates in coagulation, fibrinolysis, complement and contact system activation. So far, mutations in the factor XII gene were linked to the rare coagulation disorder Hagemann factor ...

Schnitzler Syndrome Clinical Presentation
http://emedicine.medscape.com/article/1050761-clinical

Feb 2nd, 2023 - History All patients with Schnitzler syndrome present with a chronic, recurrent, urticarial eruption. Pruritus is usually absent at the disease onset, but lesions may become mildly pruritic in approximately 45% of patients after 3-4 years. The ski...

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
https://clinicaltrials.gov/ct2/show/NCT04739059

Feb 2nd, 2023 - This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)

see more →

Guidelines  5 results

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.15214
Allergy Maurer M, Magerl M et. al.

Jan 11th, 2022 - Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidanc...

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.13384
Allergy Maurer M, Magerl M et. al.

Jan 11th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

A consensus parameter for the evaluation and management of angioedema in the emergency ...
https://doi.org/10.1111/acem.12341
Academic Emergency Medicine : Official Journal of the Soc... Moellman JJ, Bernstein JA et. al.

Apr 16th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...

A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, an...
https://doi.org/10.1016/j.jaci.2013.03.034
The Journal of Allergy and Clinical Immunology; Zuraw BL, Bernstein JA et. al.

Jun 4th, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

International consensus and practical guidelines on the gynecologic and obstetric manag...
https://doi.org/10.1016/j.jaci.2011.11.025
The Journal of Allergy and Clinical Immunology; Caballero T, Farkas H et. al.

Dec 27th, 2011 - There are a limited number of publications on the management of gynecologic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH). We sought to elaborate guidelines for optimizing the managem...

see more →

Drugs  912 results see all →

Clinicaltrials.gov  188 results

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)
https://clinicaltrials.gov/ct2/show/NCT04278885

Feb 2nd, 2023 - Factor XII is a serine protease with diverse functions that participates in coagulation, fibrinolysis, complement and contact system activation. So far, mutations in the factor XII gene were linked to the rare coagulation disorder Hagemann factor ...

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
https://clinicaltrials.gov/ct2/show/NCT04739059

Feb 2nd, 2023 - This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)

Berotralstat Treatment in Children With Hereditary Angioedema
https://clinicaltrials.gov/ct2/show/NCT05453968

Feb 1st, 2023 - This is a single-arm, open-label study designed to evaluate the PK and safety of berotralstat weight-based treatment for the prevention of hereditary angioedema attacks in pediatric participants 2 to < 12 years of age. This study will consist of t...

Perioperative Hypersensitivity in Children
https://clinicaltrials.gov/ct2/show/NCT05706246

Jan 31st, 2023 - Patients with intraoperative signs of diffuse erythema, urticaria, angioedema, sudden hypotension, tachycardia, bradycardia, arrhythmia, bronchospasm, vomiting, difficulty in ventilation, and end-tidal carbon dioxide (CO2) increase were included i...

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
https://clinicaltrials.gov/ct2/show/NCT05505916

Jan 30th, 2023 - This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.

see more →

News  280 results

Tyre Nichols' 19-Minute Wait; Judge Uses ChatGPT in Ruling; WHO Report Angers Russia
https://www.medpagetoday.com/emergencymedicine/emergencymedicine/102969

Feb 6th, 2023 - Note that some links may require subscriptions. Nineteen minutes. That's how long two emergency medical technicians waited before providing care to Tyre Nichols after he was beaten by Memphis police. (New York Times) Declared dead at an Alzheimer'...

Carotid Plaque & Hearing Loss; Exercise Intervention for Afib; MitraClip Lock Issue
https://www.medpagetoday.com/cardiology/prevention/102775

Jan 24th, 2023 - In the Atherosclerosis Risk in Communities cohort, people with carotid atherosclerosis in mid-life were more likely to have worse hearing decades later. (JAMA Otolaryngology-Head & Neck Surgery) Higher HDL cholesterol corresponded with a higher ri...

Chronic Urticaria During Pregnancy: Study Analyzes Outcomes, Treatments
https://www.medscape.com/viewarticle/982304

Oct 12th, 2022 - Most patients with chronic urticaria (CU) used treatment during pregnancy, especially with second-generation antihistamines, which appear to be safe regardless of the trimester. In addition, the rates of preterm births and medical problems of newb...

How do patients with chronic urticaria fare during pregnancy?
https://www.mdedge.com/dermatology/article/258561/medical-dermatology/how-do-patients-chronic-urticaria-fare-during
Doug Brunk

Oct 11th, 2022 - Most patients with chronic urticaria (CU) used treatment during pregnancy, especially with second-generation antihistamines, which appear to be safe regardless of the trimester. In addition, the rates of preterm births and medical problems of newb.

Lower Entresto Doses Suffice in the Real World
https://www.medpagetoday.com/cardiology/chf/101147

Oct 10th, 2022 - Heart failure patients unable to reach the target dose of angiotensin receptor/neprilysin inhibitor (ARNI) therapy still reaped gains in health status a year later, according to a post hoc analysis of PROVE-HF. People taking sacubitril/valsartan (...

see more →

Patient Education  11 results see all →